LEO Pharma Delivers 7% Revenue Growth at CER in H1 2025 and Achieves Key Milestones Enabling Future Growth
Highlights
LEO Pharma's revenue increased by 6% year-on-year to DKK 6,789 million, and by 7% at constant exchange rates (CER) entirely driven by organic growth. The revenue growth was led by North America (+28% at CER), with Europe (+1% at CER) and Rest of World (+4% at CER) also contributing to the overall growth.
Revenue from the Dermatology portfolio grew by 8% (CER) year-on-year, driven by the Strategic brands Adtralza ® /Adbry ® and Anzupgo ®, which combined had a revenue increase of 51% (CER). Sales in the Critical Care portfolio (formerly called 'Thrombosis') declined by 3% (CER) year-on-year, affected by the reversal of sales discounts in the same period last year.
Operating profit improved significantly, with adjusted EBITDA reaching DKK 1,456 million in H1 2025, reflecting a margin of 21% (H1 2024: 9%) excluding the STAT6 partnership upfront payment from Gilead received in January and other non-recurring items.
Net profit for H1 2025 was DKK 1,977 million (H1 2024: negative DKK 761 million), including non-recurring items.
Free cash flow was DKK 1,469 million for H1 2025 (H1 2024: negative DKK 779 million), and net interest-bearing debt was reduced to DKK 9,676 million (YE 2024: DKK 11,115 million). Excluding M&A, free cash flow was negative DKK 158 million driven by timing and non-recurring one-offs.
On 23 July, LEO Pharma received FDA approval of Anzupgo® (delgocitinib) for the treatment of chronic hand eczema, enabling launch of the product in the U.S. by Q3 2025 as the first and only topical pan-JAK inhibitor. Additionally, LEO Pharma on 9 July announced positive interim results from the phase 3 ADHAND trial for Adtralza®/Adbry® (tralokinumab).
On 14 July, LEO Pharma announced a partnership with Boehringer Ingelheim, granting LEO Pharma an exclusive global license for the development and commercialization of SPEVIGO® (spesolimab), a first-in-class IL-36R antagonist already approved and marketed for generalized pustular psoriasis (GPP). The partnership aims to accelerate and broaden access for patients by leveraging LEO Pharma's global dermatology platform. The transaction is expected to close in H2 2025 with SPEVIGO® set to become the third Strategic brand in LEO Pharma's portfolio, alongside Adtralza®/Adbry® and Anzupgo®.
For the 2025 outlook, group revenue growth is now expected to be 7-9% at CER (previously: 6-9%) and the adjusted EBITDA margin is now expected to be 16-18% (previously: 15-18%). This reflects the FDA approval of Anzupgo® and year-to-date business performance. The outlook does not include any impact from the partnership for SPEVIGO®, pending closing of the transaction.
LEO Pharma is in its strongest position in years – financially, strategically, and in terms of our portfolio and pipeline activities. The FDA approval of Anzupgo® represents a major step forward, and together with the addition of SPEVIGO® to our portfolio, we are further unlocking the value of our global platform, highlighting our commitment to driving innovation for patients.'
CEO Christophe Bourdon.
About LEO Pharma
LEO Pharma is a global leader in medical dermatology. We deliver innovative solutions for skin health, building on a century of experience with breakthrough medicines in healthcare. We are committed to making a fundamental difference in people's lives, and our broad portfolio of treatments serves close to 100 million patients in over 70 countries annually. Head-quartered in Denmark, LEO Pharma has a team of 4,000 people worldwide. LEO Pharma is co-owned by majority shareholder the LEO Foundation and, since 2021, Nordic Capital. For more information, visit www.leo-pharma.com.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
a minute ago
- Business Wire
SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Unicycive Therapeutics
NEW YORK--(BUSINESS WIRE)-- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Unicycive Therapeutics, Inc. ('Unicycive' or the 'Company') (NASDAQ: UNCY) and reminds investors of the October 14, 2025 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See As detailed below, the complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose that: (i) Unicycive's readiness and ability to satisfy the FDA's manufacturing compliance requirements was overstated; (ii) the OLC NDA's regulatory prospects were likewise overstated; and (iii) as a result, Defendants' public statements were materially false and misleading at all relevant times. On June 10, 2025, Unicycive issued a press release "announcing an update on its [NDA] for [OLC] to treat hyperphosphatemia in patients with [CKD] on dialysis." Therein, the Company disclosed that the FDA "had identified deficiencies in cGMP [current good manufacturing practice] compliance at a third-party manufacturing vendor"-specifically, a third-party subcontractor of Unicycive's contract development and manufacturing organization ("CDMO")-"following an FDA inspection" and that, "given the identified deficiencies, any label discussions between the FDA and the Company are precluded." On this news, Unicycive's stock price fell $3.68 per share, or 40.89%, to close at $5.32 per share on June 10, 2025. Then, on June 30, 2025, Unicycive issued a press release announcing that the FDA had issued a Complete Response Letter for the OLC NDA, citing the previously identified cGMP deficiencies at the third-party subcontractor of its CDMO. On this news, Unicycive's stock price fell $2.03 per share, or 29.85%, to close at $4.77 per share on June 30, 2025. The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class who is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Your ability to share in any recovery is not affected by the decision to serve as a lead plaintiff or not. Faruqi & Faruqi, LLP also encourages anyone with information regarding Unicycive's conduct to contact the firm, including whistleblowers, former employees, shareholders and others. To learn more about the Unicycive Therapeutics class action, go to or call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). Follow us for updates on LinkedIn, on X, or on Facebook. Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP ( Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.
Yahoo
30 minutes ago
- Yahoo
Many people using OTC birth control pills previously used nothing, study finds
Two years after the U.S. Food and Drug Administration approved the first over-the-counter birth control pill, new research is looking at who's switching to it and why. In the study, published Monday in JAMA Network Open, researchers used survey data from 986 people, ages 15 to 45, in 44 states who obtained the over-the-counter pill either online or at a pharmacy. They found that a significant portion of users shifted to the over-the-counter pill from a less-effective method of birth control or from using no contraception at all. Of those surveyed, they found a 31.8 percentage point increase in use by people who previously used no contraceptive method. A 41 percentage point increase was seen in those who switched from a less-effective method, like condoms or emergency contraception. Opill, the over-the-counter, progestin-only pill from drugmaker Perrigo, provides an option for obtaining oral contraceptives without needing to first see a health care provider. Allowing people to access the pill without a prescription was done in hopes of reducing barriers to access, according to the FDA's news release at the time of approval, which noted that almost half of the 6.1 million pregnancies in the U.S. each year are unintended. The new research "is one of the first studies to show that over-the-counter birth control pills are reaching the very people they're meant to help — those who face the greatest barriers to care," lead author Dr. Maria Rodriguez, professor of obstetrics and gynecology in the Oregon Health & Science University School of Medicine, said in a news release. Those accessing the over-the-counter pill were more likely than prescription users to be uninsured, younger (ages 15-20) and living in rural areas, according to the study. The most common reason people gave in the survey for choosing the OTC pill was that it didn't require an appointment, followed by those who said they didn't have a regular physician. "At a time when pregnancy is becoming even more dangerous in the United States — especially for people of color, those with low incomes, and those living in rural communities — our findings underscore that OTC contraception is a powerful tool for reproductive autonomy," Rodriguez said. Alaska Sen. Dan Sullivan on the Trump-Putin summit, sanctions and more Laufey on creating her own sound A robotics activist's remarkable crusade Solve the daily Crossword
New York Times
32 minutes ago
- New York Times
A Common Weight Loss Drug Can Treat Severe Liver Disease, F.D.A. Says
The Food and Drug Administration approved the weight loss drug Wegovy to treat an increasingly prevalent liver disease on Friday. Roughly 15 million people — six percent of adults in the United States — have metabolic dysfunction-associated steatohepatitis, known as MASH. Rates of the disease are rising. The condition occurs when fat builds up in the liver, which can trigger scarring, cell damage and inflammation. MASH can lead to liver cancer and even death; it is also one of the most common reasons Americans seek liver transplants. Wegovy, which is a weekly injection, is now approved for adults with MASH and moderate-to-advanced levels of fibrosis, or excessive scar tissue in the liver. The drug is not intended for people with cirrhosis, a condition marked by severe liver scarring and damage. Novo Nordisk, the company that makes Wegovy and its sister drug, Ozempic, asked regulators to green-light the new approval after submitting data from a highly anticipated clinical trial. In the study, around 63 percent of people who took the drug saw fat and inflammation clear up in their livers, without worsening liver scarring, compared to about 34 percent of participants on a placebo. 'It's definitely exciting, and helping move beyond the stigma that we're just cosmetically treating weight,' said Dr. Andrew Kraftson, a clinical associate professor in the division of metabolism, endocrinology and diabetes at Michigan Medicine. 'There are these metabolic benefits that we're seeing with these medicines.' Scientists don't entirely understand how the drug helps treat MASH. It may, in part, be as simple as weight loss: MASH is closely linked with obesity, and Wegovy lowers body weight. But researchers think the drug may have other beneficial effects, like potentially reducing inflammation in the liver. Want all of The Times? Subscribe.
